- Home
- COLL vs GDEN Comparison
COLL vs GDEN Comparison
Compare COLL & GDEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COLL
- GDEN
- Stock Information
- Founded
- COLL 2002
- GDEN 1998
- Country
- COLL United States
- GDEN United States
- Employees
- COLL N/A
- GDEN N/A
- Industry
- COLL Biotechnology: Pharmaceutical Preparations
- GDEN Services-Misc. Amusement & Recreation
- Sector
- COLL Health Care
- GDEN Consumer Discretionary
- Exchange
- COLL Nasdaq
- GDEN Nasdaq
- Market Cap
- COLL 910.2M
- GDEN 888.7M
- IPO Year
- COLL 2015
- GDEN 1999
- Fundamental
- Price
- COLL $29.71
- GDEN $26.52
- Analyst Decision
- COLL Strong Buy
- GDEN Strong Buy
- Analyst Count
- COLL 5
- GDEN 7
- Target Price
- COLL $43.60
- GDEN $37.00
- AVG Volume (30 Days)
- COLL 466.9K
- GDEN 296.3K
- Earning Date
- COLL 05-08-2025
- GDEN 05-07-2025
- Dividend Yield
- COLL N/A
- GDEN 3.63%
- EPS Growth
- COLL 43.56
- GDEN N/A
- EPS
- COLL 1.86
- GDEN 1.71
- Revenue
- COLL $631,449,000.00
- GDEN $666,818,000.00
- Revenue This Year
- COLL $19.43
- GDEN $2.74
- Revenue Next Year
- COLL $3.34
- GDEN $2.57
- P/E Ratio
- COLL $16.00
- GDEN $16.12
- Revenue Growth
- COLL 11.41
- GDEN N/A
- 52 Week Low
- COLL $27.28
- GDEN $25.17
- 52 Week High
- COLL $42.29
- GDEN $36.92
- Technical
- Relative Strength Index (RSI)
- COLL 48.90
- GDEN 36.03
- Support Level
- COLL $29.33
- GDEN $26.74
- Resistance Level
- COLL $30.84
- GDEN $28.35
- Average True Range (ATR)
- COLL 0.85
- GDEN 1.13
- MACD
- COLL 0.08
- GDEN 0.11
- Stochastic Oscillator
- COLL 50.11
- GDEN 39.59
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About GDEN Golden Entertainment Inc.
Golden Entertainment Inc is a U.S. based company that focuses on distributed gaming, casino, and resort operations. Its reportable segments are Nevada Casino Resorts, Nevada Locals Casinos, Nevada Taverns, and Distributed Gaming. The majority of the revenue for the company is generated from its Nevada Casino Resorts segment which is comprised of destination casino resort properties offering a variety of food and beverage outlets, entertainment venues, and other amenities.